Innoviva Q3 2023: GSK royalties $57M, net income $82M, launches XACDURO, positive Phase 3 zoliflodacin

Innoviva, Inc.

2023-Q3 EPS reported $1.45 revenue$224,623,000

GSK royalty revenue $57.0M (Q3 2023) vs $65.6M (Q3 2022); net product sales $13.7M.
Net income $82.0M ($1.26 basic EPS) vs $265.5M ($3.81) in Q3 2022; prior year included gain on sale.
Launched XACDURO for Acinetobacter HABP/VABP; announced positive Phase 3 zoliflodacin for gonorrhea.
Appointed Stephen Basso as CFO; repurchased $11.0M of stock in Q3.
Cash $180.0M; invested $25M in Armata Pharmaceuticals.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Innoviva, Inc. reported the third quarter ended September 30, 2023 results: net income $82.0 million, EPS $1.26 basic per share.

Period: the third quarter ended September 30, 2023
Net income: $82.0 million
EPS: $1.26 basic per share
Result: reported results

Exact text from the filing

On November 1, 2023, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-113410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.